Literature DB >> 20146698

The progression of pathology in Parkinson's disease.

Glenda Margaret Halliday1, Heather McCann.   

Abstract

To identify the progression of pathology over the entire course of Parkinson's disease, we longitudinally followed a clinical cohort to autopsy and identified three clinicopathological phenotypes that progress at different rates. Typical Parkinson's disease has an initial rapid loss of midbrain dopamine neurons with a slow progression of Lewy body infiltration into the brain (over decades). Dementia intervenes late when Lewy bodies invade the neocortex. Older onset patients (> 70 years old) dement earlier and have much shorter disease durations. Paradoxically, they have far more alpha-synuclein-containing Lewy bodies throughout the brain, and many also have additional age-related plaque pathology. In contrast, dementia with Lewy bodies has the shortest disease course, with substantive amounts of Lewy bodies and Alzheimer-type pathologies infiltrating the brain. These data suggest that two age-related factors influence pathological progression in Parkinson's disease--the age at symptom onset and the degree and type of age-related Alzheimer-type pathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146698     DOI: 10.1111/j.1749-6632.2009.05118.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  65 in total

Review 1.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  The pattern of gray matter atrophy in Parkinson's disease differs in cortical and subcortical regions.

Authors:  Mechelle M Lewis; Guangwei Du; Eun-Young Lee; Zeinab Nasralah; Nicholas W Sterling; Lijun Zhang; Daymond Wagner; Lan Kong; Alexander I Tröster; Martin Styner; Paul J Eslinger; Richard B Mailman; Xuemei Huang
Journal:  J Neurol       Date:  2016-01       Impact factor: 4.849

Review 3.  RNAi medicine for the brain: progresses and challenges.

Authors:  Ryan L Boudreau; Edgardo Rodríguez-Lebrón; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2011-03-31       Impact factor: 6.150

4.  Cumulative exposure to lead and cognition in persons with Parkinson's disease.

Authors:  Jennifer Weuve; Daniel Z Press; Francine Grodstein; Robert O Wright; Howard Hu; Marc G Weisskopf
Journal:  Mov Disord       Date:  2012-11-09       Impact factor: 10.338

Review 5.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

6.  The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat.

Authors:  Kobra Zare; Akram Eidi; Mehrdad Roghani; Ali Haeri Rohani
Journal:  Metab Brain Dis       Date:  2014-08-16       Impact factor: 3.584

Review 7.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 8.  Cognition in movement disorders: where can we hope to be in ten years?

Authors:  David Burn; Daniel Weintraub; Bernard Ravina; Irene Litvan
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

9.  Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease.

Authors:  Ilknur Telkes; Ashwin Viswanathan; Joohi Jimenez-Shahed; Aviva Abosch; Musa Ozturk; Akshay Gupte; Joseph Jankovic; Nuri F Ince
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-21       Impact factor: 11.205

Review 10.  Dementia and neuroimaging.

Authors:  Federica Agosta; Francesca Caso; Massimo Filippi
Journal:  J Neurol       Date:  2012-12-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.